Participated · Equity · Apr 2026

Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

Led · Seed · Mar 2026

Prickly Pear Health offers a NextGen digital platform that combines voice AI, behavioral analytics, and wearable data to deliver personalized insights about how hormonal fluctuations affect cognitive and emotional health. The platform targets symptoms such as brain fog, stress, and memory changes across pregnancy, postpartum, irregular cycles, perimenopause, and menopause. Since launching in 2024, the company has surpassed 2,000 active users in its current phase and is developing toward a broader public launch. With the expanded pre-seed funding, Prickly Pear plans to accelerate user growth and begin expanding deployments with mental health practices starting in Arizona. The company positions itself to build a new category within digital brain health by integrating hormonal science with personalized technology. Financially, it has raised more than $600,000 in pre-seed capital with participation from Emmeline Ventures, Bayless Ventures, and AZ Venture Capital Inc.

Participated · Series A · Sep 2025

Lōvu Health operates an AI-powered digital maternal health platform that personalizes care from conception through two years postpartum, combining remote patient monitoring, clinician dashboards, care navigation, and a curated marketplace of third-party vendors. The platform captures fetal heart rate, maternal blood pressure, weight, heart rate, and mental-health assessments in a dynamic dashboard that alerts clinicians to meaningful changes and reduces administrative burden. Lōvu reports clinical impact metrics including earlier identification of preeclampsia for 6% of mothers, detection of depression and anxiety in upwards of 30% of clinical populations, and identification of 57% of mothers on the platform with chronic hypertension. Its marketplace includes more than 50 specialty vendors—doula support, lactation, pelvic floor therapy, mental health and others—and can shorten time to mental-health appointments by up to four months. The company plans to use new funding to expand AI capabilities (including three planned augmentative agents), and to invest in automation, integrations, and headcount as it scales to meet clinician and patient demand. Lōvu positions itself as a care-extension to obstetricians to improve access and outcomes, particularly for underserved and Medicaid populations.

Led · Seed · Aug 2024

WealthMore is a consumer investment platform built to broaden access to wealth advisers through adviser-led portfolios, licensed advisers, and financial planning. The product requires a $5,000 minimum and offers three pricing tiers starting at $25 per month. The company partnered with Apex Clearing Corporation for brokerage services and has built community features such as #firstgenwealth and #blkwomenwealth to engage users. WealthMore launched a beta in June and plans to exit beta around the end of the year. The founder, Mical Jeanlys-White, drew on prior product experience at American Express and JPMorgan Chase and has focused on diverse advisers and grassroots brand-building including lifestyle products and community events. The team currently numbers 10 people and conducted surveys of over 300 potential users while designing pricing and features.

Participated · Seed · Oct 2023

MDisrupt is an Austin, TX–based marketplace serving the health tech and life sciences industries. Its AI-powered Health Expert Marketplace connects companies with over 2,500 professionals, including clinicians, health system executives, and payor leaders. The platform streamlines access to essential expertise to enable rapid product development and validation. The company raised $1M in funding led by American Heart Association Ventures, and Lisa Suennen joined the MDisrupt board. MDisrupt says it will use the funds to support expanded adoption of its AI-powered marketplace and to add new features through a strategic collaboration with the Association to meet members' needs. The company is led by CEO and founder Ruby Gadelrab. MDisrupt is a marketplace that connects healthtech and life science companies with health experts to help build, commercialize and scale health products. Led by founder and CEO Ruby Gadelrab and based in Austin, TX, the company reports a network of over 1,500 experts from organizations including Blue Cross Blue Shield, CVS, Willis Towers Watson, the U.S. FDA, Optum, and Cleveland Clinic. MDisrupt serves both startups and enterprise customers across healthtech and life science sectors. The company raised $3M in Seed funding and intends to use the capital to launch its platform and expand its client roster. In conjunction with the round, Cat Middleton of The Venture Collective is joining the MDisrupt board of directors. MDisrupt is transforming into a digital health intelligence company that organizes the world's digital health products by performance through clinically crowdsourced data generation. Founded in 2019 and based in Austin, Texas, it connects digital health companies with health industry experts and has helped more than 55 companies build and scale products. The company's platform combines three elements—people, platform, and data—to digitize solutions for access to experts on demand, clinical early adopters, and real-world performance data. MDisrupt plans to expand the platform to enable innovators to rapidly generate the real-world performance data needed to commercialize and scale their products and to serve as a marketplace and benchmark for the industry. The platform's objective dataset, built on real-world clinical performance from every digital health product on the platform, will feed its digital health intelligence engine. The company says the output will influence key decision-makers and provide standards and benchmarks for the growing digital health sector.